Posted on 23 December, 2014 33rd Annual J.P. Morgan Healthcare Conference, San Francisco January 12-15, 2015

Posted on 3 November, 2014   Merus to present at the annual Protein & Antibody Engineering Summit (PEGS), Lisbon on November 4, 2014.

Posted on 18 September, 2014 In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013,

Posted on 4 March, 2014 Under the terms of the agreement, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX® technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead products, a bispecific anti-cancer antibody.